Survodutide Once Weekly for the Treatment of Adults with Obesity
Autores: le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, et al.
Revista
N Engl J Med
Año
2026
Citas
200
Type
Research Article
Subject
Human
Condition
Obesity / Type 2 Diabetes
TL;DR
Phase 3 trial of once-weekly survodutide (GLP-1/glucagon dual agonist) for obesity treatment in adults, building on promising Phase 2 weight loss results.
Ver Artículo
DOI: 10.1056/NEJMoa2600751
Abstract
Study investigating Survodutide: Survodutide Once Weekly for the Treatment of Adults with Obesity.